In the model yeast Saccharomyces cerevisiae, RAD53 mutants are more sensitive than the wild type to DNA damage and fail to slow cell cycle progression (10); in humans, mutations in CHK2 are associated with increased breast cancer risk (11). Here, CHEK2 is linked to breast carcinoma.